Puretrop Fruits Limited reported a net profit of ₹456.53 lakh for the quarter ended June 30, 2026, marking a substantial year-on-year increase from ₹60.78 lakh in Q1FY25. Revenue from operations stood at ₹2,802.51 lakh, slightly higher than the ₹2,794.46 lakh recorded in the same quarter last year. The Board of Directors approved these unaudited financial results on August 7, 2026, alongside key leadership changes that will be put to shareholders at the upcoming Annual General Meeting.

The profit surge was driven by improved operational efficiency and lower tax expenses relative to revenue growth. While revenue grew marginally by 0.3% year-on-year, the profit before tax jumped to ₹531.48 lakh from ₹58.64 lakh in Q1FY25. This divergence highlights a significant expansion in operating margins, supported by effective cost management and inventory adjustments. Statutory Auditors M/s. FP & Associates issued a limited review report on the financial statements.

Key Financial Metrics

Note: Previous year's figures have been regrouped and reclassified where necessary.

Board Appointments and Re-Appointments

The Board appointed Mr. Saikiran Saladi (DIN: 06958710) as an Additional Director in the capacity of an Independent Director. His appointment is valid for two years, from August 7, 2026, to August 6, 2028, subject to shareholder approval via special resolution. Mr. Saladi brings expertise in infrastructure layout design and strategic decision-making based on market trends.

Additionally, the Board sought shareholder approval for the re-appointment of three directors:

• Pradeep Katyal (DIN: 10727156) as an Independent Director for five years, from August 9, 2026, to August 8, 2031.
• Sharada Iyer (DIN: 03357928) as an Independent Director for five years, from August 9, 2026, to August 8, 2031.
• Nanita Ashok Motiani (DIN: 00787809) as a Whole Time Director for two years, liable to retire by rotation, effective April 1, 2027.

What the Numbers Show

The most striking aspect of Puretrop’s Q1FY26 performance is the decoupling of revenue growth from profit expansion. While top-line growth was modest at 0.3%, net profit increased by over six times compared to the previous year. This suggests that the company has successfully optimized its cost structure or benefited from favorable inventory valuation changes, which totaled ₹3,335.85 lakh in reductions during the quarter. Investors should monitor whether this margin expansion is sustainable or influenced by one-time inventory adjustments.

Corporate Actions and AGM Details

The Board approved the Draft Directors’ Report for FY25-26 and scheduled the 34th Annual General Meeting (AGM) for September 15, 2026, at 4:00 P.M. IST. The meeting will be conducted through Video Conferencing or Other Audio-Visual Means (OAVM), in compliance with Ministry of Corporate Affairs and SEBI circulars. M/s. Manoj Hurkat & Associates has been appointed as the Scrutinizer, and National Securities Depository Limited (NSDL) will serve as the Remote E-Voting Agency.

Independent Director Ashok Chandumal Murajani has resigned from the Board of puretrop fruits effective June 18, 2026, due to an underlying medical condition. The resignation was intimated to BSE Limited under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Murajani confirmed there are no material reasons for his departure other than the health issues cited in his resignation letter.

Consequent to his resignation, Murajani has ceased to hold key positions on various board committees. He stepped down as the Chairman of the Audit Committee, Nomination and Remuneration Committee, and Stakeholders Relationship Committee. Additionally, he is no longer a member of the Corporate Social Responsibility Committee.

Details of Resignation

The company disclosed the specific details regarding the change in directorship in an annexure to the regulatory filing. The following table summarizes the event information:

In his resignation letter addressed to the Chairman, Murajani stated that ongoing health issues and medical advice rendered him unable to fulfill his duties with the required level of commitment and attention. He expressed that stepping down was in the best interests of the company. The company placed on record its appreciation for his valuable contribution and guidance during his tenure as a Non-Executive Independent Director.